

Performance Assessment of the LIAISON® SARS-CoV-2 Antigen Assay On Nasopharyngeal Swabs

Andreina Baj^{1,2,#}, Cristian Zago^{2,#}, Antonio Tamborini², Alberto Colombo², Gianluca Cassani², Agostino Rossi², Renee Pasciuta², Federica Novazzi², Martina Prestia², Riccardo Capuano², Angelo Genoni¹, Lorenzo Azzi³, Daniela Dalla Gasperina¹, Pietro Giorgio Spezia⁴, Daniele Focosi⁵, Fabrizio Maggi^{1,2}

¹Department of Medicine and Surgery, University of Insubria, Varese, Italy;

²Laboratory of Microbiology, ASST Sette Laghi, Varese, Italy;

³Unit of Oral Medicine and Pathology, ASST Sette Laghi, Varese, Italy;

⁴Department of Translational Research, University of Pisa, Italy;

⁵North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy

These authors contributed equally to this work.

SUMMARY

The SARS-CoV-2 pandemic is ongoing worldwide, causing prolonged pressure on molecular diagnostics. Viral antigen (Ag) assays have several advantages, ranging from lower cost to shorter turnaround time to detection. Given the rare occurrence of low-load viremia, antigen assays for SARS-CoV-2 have focused on nasopharyngeal swab and saliva as biological matrices, but their effectiveness must be validated. We assayed here the performances of the novel quantitative Liaison® SARS-CoV-2 Ag assay on 119 nasopharyngeal swabs and obtained results were compared with Hologic Panther and Abbott m2000 RT-qPCR. The Ag assay demonstrated a good correlation with viral load, shorter turnaround time, and favorable economics. The best performance was obtained in the acute phase of disease.

Received June 01, 2021

Accepted November 04, 2021

INTRODUCTION

The ongoing COVID-19 pandemic has caused 248 million cases and 5 million deaths worldwide as of November 3, 2021. The pandemic has been a challenge for both wards and laboratories, with great pressure exerted on molecular diagnostics, namely SARS-CoV-2 RT-PCR. The supply of PCR reagents has often suffered shortages during the pandemic, and alternative direct or indirect diagnosis has been implemented. Antigen (Ag) assays have a timeframe of usability like that of RT-PCR, and have several advantages over molecular methods, ranging from stability to cheaper cost and shorter turnaround time. Both point-of-care (lateral-flow immunochromatographic assays (LFIA)) and laboratory setting (high-throughput instrument-based) Ag tests for SARS-CoV-2 have been re-

leased, with the former category, unfortunately, offering poor performance in terms of assay precision (Houston *et al.*, 2021, Gremmels *et al.*, 2021, James *et al.*, 2021, Schildgen *et al.*, 2021, Möckel *et al.*, 2021, Favresse *et al.*, 2021, Osterman *et al.*, 2021, Young *et al.*, 2020, Yamayoshi *et al.*, 2020).

We report here our experience with the use of the Liaison® SARS-CoV-2 Ag assay (DiaSorin, Saluggia, Italy).

MATERIALS AND METHODS

Nasopharyngeal swab specimens

Residual diagnostic samples from 119 consecutive nasopharyngeal swabs (NPS), placed into sterile universal transport medium, were used for the study. Samples were randomly chosen from patients hospitalized in COVID-dedicated wards, with a mean age of 78 (28-95), a clinical picture spanning from mild to critical, and in a period ranging from 0 to 95 days after the diagnosis of infection.

Molecular tests confirmed 92 samples as SARS-CoV-2 positive and 27 as virus-negative. After routine testing, aliquots of specimens were taken and stored at -80°C until use.

Key words:

SARS-CoV-2, COVID-19, Spike; antigen assay, molecular assays.

Corresponding author:

Andreina Baj

E-mail: andreina.baj@uninsubria.it

SARS CoV-2 genome detection

NPS had previously been tested for SARS-CoV-2 RNA using two different molecular platforms. The real-time SARS-CoV-2 assay (Abbott Molecular, Des Plaines, IL) is a qualitative test performed on the Abbott m2000 platform and targets the N and RNA dependent RNA polymerase (RdRp) genes of the viral genome.

The Aptima assay (Hologic, San Diego, CA) uses transcription-mediated amplification technology for SARS-CoV-2 RNA amplification. It targets two regions within the ORF1ab gene of the viral genome and is performed on the Panther instrument.

SARS CoV-2 Ag detection

On NPS samples previously analyzed by molecular methods, the LIAISON® SARS-CoV-2 Ag (DiaSorin, Saluggia, Italy) was performed according to the manufacturer's recommendations. The assay is a direct two-step sandwich chemiluminescence immunoassay, and quantitatively detects SARS-CoV-2 nucleocapsid protein Ag in NPS by using the LIAISON® XL analyzer. The analyzer automatically calculates SARS-CoV-2 Ag concentrations from 22 to 10⁵ TCID₅₀/mL.

Statistical analysis

SPSS software version 23 (IBM, Chicago, IL, USA) was used for statistical analysis. Transformed Ag load in Log format was used for analysis. Chi-square test and Fisher's exact test were applied to evaluate the heterogeneity of contingency tables. The coefficient of determination R² (Spearman rho coefficient) was used to measure the overall correlation between methods. To test the repeatability of the Ag method, four samples were tested in quadruplicate, and the coefficient of variation (CV) was calculated. All *p* values presented are based on two-tailed tests, and *p*<0.05 was considered statistically significant.

RESULTS

The 119 randomly selected NPS were tested both by molecular and antigenic methods. Considering the 92 molecular-positive specimens, 84% (77) were detected as positive when the LIAISON® SARS-CoV-2 Ag was applied, whereas 100% (27) of samples molecularly detected as virus negative also tested negative by the Ag assay. Overall, the Ag assay concordance was 87% (104 of 119 samples), with good agreement.




Figure 1 - A) Correlation of Liaison® SARS-CoV-2 Ag assay readings ($\log\text{TCID}_{50}/\text{ml}$) with cycle threshold values on Abbott m2000 RT-qPCR. B) Correlation of Liaison® SARS-CoV-2 Ag assay readings ($\log\text{TCID}_{50}/\text{ml}$) with RLU values on Hologic Panther TMA.

Table 1 - Percentage of positive Liaison® SARS-CoV-2 Ag assay readings according to different cycle threshold ranks in Abbott m2000.

Cycle threshold value (Abbott m2000)	No. examined	Liaison® SARS CoV-2 Ag	
		Positive (%)	TCID ₅₀ per ml (mean ± standard error)
< 22	35	35 (100)	17039 ± 5649
22 - 26	25	16 (64)	3902 ± 2681
> 26	7	3 (43)	30 ± 3
Total	67	54 (81)	12051 ± 3776

Table 2 - Percentage of positive Liaison® SARS-CoV-2 Ag assay readings according to different RLU ranks in Hologic Panther.

RLU (Hologic, Panther)	No. examined	Liaison® SARS CoV-2 Ag	
		Positive (%)	TCID ₅₀ per ml (mean ± standard error)
< 1246	13	12 (92)	19833 ± 11097
≥ 1246	12	11 (92)	15678 ± 9579
Total	25	23 (92)	17846 ± 7230

Table 3 - Reproducibility of Liaison® SARS-CoV-2 Ag assay readings.

Sample/Ct value (Abbott m2000)	Liaison® SARS-CoV-2 Ag assay determination (TCID ₅₀ /ml)				CV value
	A	B	C	D	
1 / 22	1523	1458	1500	1484	0.018
2 / 24	371	363	362	372	0.014
3 / 25	208	213	203	201	0.026
4 / 26	186	184	188	181	0.016

Table 4 - Summary of high-throughput, laboratory setting SARS-CoV-2 Ag assays for use with nasal swabs, nasopharyngeal swabs, or oropharyngeal swab. N: nucleocapsid. S: spike.

Vendor	Instrument	Kit brand	Ag	Method	TAT (min)	Ref
Roche	Cobas e411 analyzer, cobas e601/e602 modules, cobas e801 module	Elecsys® SARS-CoV-2 Antigen	N	One-step double Ab sandwich IA	18	n.a. https://diagnostics.roche.com/global/en/products/params/electsys-sars-cov-2-antigen-test.html
DiaSorin	LIAISON® XL, LIAISON® XS and LIAISON®	Liaison® SARS-CoV-2 Ag	N	Sandwich IA	42	Lefever <i>et al.</i> , 2021, Häuser <i>et al.</i> , 2021, Hartard <i>et al.</i> , 2021 https://www.diasorin.com/sites/default/files/allegati_prodotti/liaisonr_sars_cov_2_antigen_pag_sing_m0870004372_a_digital_lr.pdf
BBB Inc. (by Celltrion USA, Inc.)	SAMPINUTE™ Analyzer	Sampinute COVID-19 Antigen MIA	RBD	Magnetic Electrochemical Sandwich IA (MESIA)	10	n.a. https://www.celltrion.com/en-us/kit/sampinute
Quidel Corporation	Sofia and Sofia 2 instrument	Sofia SARS Antigen FIA	N	Sandwich IFA	15	(Young <i>et al.</i> , 2020, Pray <i>et al.</i> , 2021, Beck <i>et al.</i> , 2021) https://www.quidel.com/sites/default/files/product/documents/EF1438903EN00.pdf
Becton, Dickinson and Company	BD Veritor™ Plus Analyzer	BD Veritor System for Rapid Detection of SARS-CoV-2	N		15	(Young <i>et al.</i> , 2020) https://www.bd.com/documents/guides/directions-for-use/IDS_BD-Veritor-Plus-SARS-CoV-2-500048916_DF_EN.pdf
Meso Scale Discovery	MSD	e S-PLEX®		Electrochemiluminescence (ECL)		(Pollock <i>et al.</i> , 2021)
Quanterix Corporation	Simoa HD-X Analyzer	Simoa® SARS-CoV-2 N Protein Antigen Test	N			n.a.
Ortho Clinical Diagnostics	VITROS 3600 Immunodiagnostic System and the VITROS 5600/XT 7600 Integrated Systems	VITROS Immunodiagnostic Products SARS-CoV-2 Antigen Reagent Pack	N			n.a.
Fujirebio	LUMIPULSE G1200	Lumipulse® G SARS-CoV-2 Ag	N		35'	(Aoki <i>et al.</i> , 2020, Hirotsu <i>et al.</i> , 2020)
Luminostics, Inc	Clip Analyzer	Clip COVID Rapid Antigen Test	N			n.a.
LumiraDx UK Ltd. SARS-CoV-2	LumiraDx Platform	LumiraDx SARS-CoV-2 Ag Test	N	Microfluidic immuno-fluorescence assay		(Kohmer <i>et al.</i> , 2021)

Interesting, a reverse correlation ($r=-0.74$) between the Liaison® SARS-CoV-2 Ag assay and the cycle threshold in Abbott m2000 RT-qPCR was observed (Figure 1A). Of note, the sensitivity of Ag assay was 84% overall when compared to Abbott m2000, but 100% for samples with Ct<22 (Table 1).

Instead, a lack of correlation was noted between Liaison® SARS-CoV-2 Ag assay and the RLU readings from Hologic Panther (Figure 1B and Table 2). This is not unexpected given the lack of a precise correlation between RLU and viral loads.

Of note, 94.4% sensitivity was observed when patients tested within 10 days post onset of symptoms, but dropped to 82% when all patients were considered, in a period ranging from 0 to 95 days after diagnosis of infection.

Finally, intra precision and reproducibility of the Ag assay were investigated by testing, in four independent experiments, a panel of 4 samples having different Ct values by Abbott platform. The differences between measured TCID₅₀/ml values were small and the mean CV variation was 0.0185 (Table 3).

DISCUSSION

Given the transient and low-grade viremia, antigen tests for SARS-CoV-2 have mainly focused on NPS and saliva as the biological matrix. Nasal and nasopharyngeal samples usually harbor higher viral loads because of the higher number of replication-competent cells, and most assays should be used within 10 days from the onset of symptoms. Assays can be classified according to the setting for usage (laboratory vs. point-of-care testing (POCT)) or according to the detected antigen (spike vs. nucleocapsid protein).

Many POCT based on immunochromatographic LFIA have entered the market (e.g., Abbott's BinaxNOW™ COVID-19 Ag Card (James *et al.*, 2021, Young *et al.*, 2020, Okoye *et al.*, 2021, Kashiwagi *et al.*, 2021) or Roche's Panbio COVID-19 Ag Rapid Test Device (Gremmels *et al.*, 2021, Mak GCK *et al.*, 2021, Linares *et al.*, 2020, Fenollar *et al.*, 2021, Fund 2021), but they generally perform worse than instrument-based antigen assays (sensitivities and specificities in the 70-80% range vs. >90%, respectively). Table 4 summarizes the currently marketed high-throughput, laboratory setting SARS-CoV-2 Ag assays for use with nasal, oropharyngeal or nasopharyngeal swab (Kashiwagi *et al.*, 2021, Chen *et al.*, 2021).

To date, few studies have compared the performance of Ag versus molecular assays in nasopharyngeal swabs, but none of them tested the effectiveness of Ag assays on SARS CoV-2 detection. The LIAISON® SARS-CoV-2 Ag arises as an alternative solution to identify acute COVID-19 infection, with a declared 94.6% sensitivity on nasopharyngeal swabs. Our study represents the first validation of the test against two robust RT-qPCR and TMA platforms, suggesting

that the Ag assay can be used reliably in the laboratory as an alternative to molecular testing whenever high viral loads are suspected and in the acute phase of the disease. In these situations, the LIAISON® SARS-CoV-2 Ag test supplies quick and reliable results, contributing to contain the virus spread.

Declaration of Conflicting Interests

We declare we have no conflicts of interest related to this manuscript.

References

- Aoki K., Nagasawa T., Ishii Y., Yagi S., Okuma S., Kashiwagi K., et al. (2020). Clinical validation of quantitative SARS-CoV-2 antigen assays to estimate SARS-CoV-2 viral loads in nasopharyngeal swabs. *J Infect Chemother.* **3**, S1341-321X(20)30428-1.
- Beck E.T., Paar W., Fojut L., Serwe J., Jahnke R.R. (2021). Comparison of the Quidel Sofia SARS FIA Test to the Hologic Aptima SARS-CoV-2 TMA Test for Diagnosis of COVID-19 in Symptomatic Outpatients. *J Clin Microbiol.* **59**, e02727-20.
- Chen C.C., Lu S.C., Bai C.H., Wang P.Y., Lee K.Y., Wang Y.H. (2021). Diagnostic Accuracy of SARS-CoV-2 Antigen Tests for Community Transmission Screening: A Systematic Review and Meta-Analysis. *Int. J. Environ. Res. Public Health.* **18**, 11451.
- Favresse J., Gillot C., Oliveira M., Cadrobbi J., Elsen M., Eucher C., et al. (2021). Head-to-Head Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-CoV-2 Infection. (2021). *J Clin Med.* **10**, 265.
- Fenollar F., Bouam A., Ballouche M., Fuster L., Prudent E., Colson P., et al. (2021). Evaluation of the Panbio COVID-19 Rapid Antigen Detection Test Device for the Screening of Patients with COVID-19. *J Clin Microbiol.* **59**, e02589-20.
- Fund T.G. (2021). List of SARS-CoV-2 Diagnostic test kits and equipments eligible for procurement according to Board Decision on Additional Support for Country Responses to COVID-19 (GF/B42/EDP11). Version 25. https://www.theglobalfund.org/media/9629/covid19_diagnosticproducts_list_en.pdf.
- Gremmels H., Winkel B.M.F., Schuurman R., Rosingh A., Rigger N.A.M., Rodriguez O., et al. (2021). Real-life validation of the Panbio™ COVID-19 antigen rapid test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection. *E Clinical Medicine.* **31**, 100677.
- Hartard, Cédric, Berger, Sibel, Josse, Thomas, Schvoerer, Evelyne and Jeulin, Hélène. (2021). Performance evaluation of an automated SARS-CoV-2 Ag test for the diagnosis of COVID-19 infection on nasopharyngeal swabs. *Clinical Chemistry and Laboratory Medicine.* **59**, 2003-2009.
- Häuser F., Sprinzl M.F., Dreis K.J., Renzaho A., Youhanen S., Kremer W.M., et al. (2021). Evaluation of a laboratory-based high-throughput SARS-CoV-2 antigen assay for non-COVID-19 patient screening at hospital admission. *Med Microbiol Immunol.* **210**, 165-171.
- Hirotsu Y., Maejima M., Shibusawa M., Nagakubo Y., Hosaka K., Amemiya K., et al. (2020). Comparison of automated SARS-CoV-2 antigen test for COVID-19 infection with quantitative RT-PCR using 313 nasopharyngeal swabs, including from seven serially followed patients. *Int J Infect Dis.* **99**, 397-402.
- Houston H., Gupta-Wright A., Toke-Bjolverud E., Biggin-Lamming J., John L. (2021). Diagnostic accuracy and utility of SARS-CoV-2 antigen lateral flow assays in medical admissions with possible COVID-19. *J Hosp Infect.* S0195-6701(21)00036-0.
- James A.E., Gulle T., Kothari A., Holder K., Garner K., Patil N. (2021). Performance of the BinaxNOW coronavirus disease 2019 (COVID-19) Antigen Card test relative to the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) assay among symptomatic and asymptomatic healthcare employees. *Infect Control Hosp Epidemiol.* **25**, 1-3.
- Kashiwagi K., Ishii Y., Aoki K., Yagi S., Maeda T., Miyazaki T., et al. (2021). Immunochromatographic test for the detection of SARS-CoV-2 in saliva. *J Infect Chemother.* **27**, 384-386.
- Kohmer N., Toptan T., Pallas C., Karaca O., Pfeiffer A., Westhaus

- S., et al. (2021). The Comparative Clinical Performance of Four SARS-CoV-2 Rapid Antigen Tests and Their Correlation to Infectivity In Vitro. *J Clin Med*. **10**, 328.
- Lefever S., Indevuyt C., Cuypers L., Dewaele K., Yin N., Cotton F., et al., Royal Belgian Society of Laboratory Medicine. (2021). Comparison of the Quantitative DiaSorin Liaison Antigen Test to Reverse Transcription-PCR for the Diagnosis of COVID-19 in Symptomatic and Asymptomatic Outpatients. *J Clin Microbiol*. **59**, e0037421.
- Linares M., Pérez-Tanoira R., Carrero A., Romanyk J., Pérez-García F., Gómez-Herruz P., et al. (2020). Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms. *J Clin Virol*. **133**, 104659.
- Mak G.C.K., Lau S.S.Y., Wong K.K.Y., Chow N.L.S., Lau C.S., Lam E.T.K., et al. (2021). Evaluation of rapid antigen detection kit from the WHO Emergency Use List for detecting SARS-CoV-2. *J Clin Virol*. **134**, 104712.
- Möckel M., Corman V.M., Stegemann M.S., Hofmann J., Stein A., Jones T.C., et al. (2021). SARS-CoV-2 Antigen Rapid Immunoassay for Diagnosis of COVID-19 in the Emergency Department. *Biomarkers*. 1-13.
- Okoye N.C., Barker A.P., Curtis K., Orlandi R.R., Snavely E.A., Wright C., et al. (2021). Performance Characteristics of BinaxNOW COVID-19 Antigen Card for Screening Asymptomatic Individuals in a University Setting. *J Clin Microbiol*. doi: 10.1128/jcm.03282-20.
- Osterman A., Baldauf H.M., Eletreby M., Wettengel J.M., Afridi S.Q., Fuchs T., et al. (2021). Evaluation of two rapid antigen tests to detect SARS-CoV-2 in a hospital setting. *Med Microbiol Immunol*. **16**, 1-8.
- Pollock N.R., Savage T.J., Wardell H., Lee R.A., Mathew A., Stengelin M., Sigal G.B. (2021). Correlation of SARS-CoV-2 nucleocapsid antigen and RNA concentrations in nasopharyngeal samples from children and adults using an ultrasensitive and quantitative antigen assay. *J Clin Microbiol*. JCM.03077-20.
- Pray I.W., Ford L., Cole D., Lee C., Bigouette J.P., Abedi G.R., et al. (2021). Performance of an Antigen-Based Test for Asymptomatic and Symptomatic SARS-CoV-2 Testing at Two University Campuses - Wisconsin, September-October 2020. *MMWR Morb Mortal Wkly Rep*. **69**, 1642-1647.
- Schildgen V., Demuth S., Lüsebrink J., Schildgen O. (2021). Limits and Opportunities of SARS-CoV-2 Antigen Rapid Tests: An Experienced-Based Perspective. *Pathogens*. **10**, 38.
- Yamayoshi S., Sakai-Tagawa Y., Koga M., Akasaka O., Nakachi I., Koh H., et al. (2020). Comparison of Rapid Antigen Tests for COVID-19. *Viruses*. **12**, 1420.
- Young S., Taylor S.N., Cammarata C.L., Varnado K.G., Roger-Dalbert C., Montano A., et al. (2020). Clinical Evaluation of BD Veritor SARS-CoV-2 Point-of-Care Test Performance Compared to PCR-Based Testing and versus the Sofia 2 SARS Antigen Point-of-Care Test. *J Clin Microbiol*. **59**, e02338-20.